PFS Investments Inc. Sells 874 Shares of Guardant Health, Inc. (NASDAQ:GH)

PFS Investments Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GHGet Rating) by 1.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,749 shares of the company’s stock after selling 874 shares during the period. PFS Investments Inc.’s holdings in Guardant Health were worth $3,163,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Research Global Investors boosted its holdings in shares of Guardant Health by 50.0% in the fourth quarter. Capital Research Global Investors now owns 7,927,702 shares of the company’s stock worth $792,929,000 after acquiring an additional 2,640,910 shares during the period. Capital International Investors boosted its holdings in shares of Guardant Health by 38.0% in the fourth quarter. Capital International Investors now owns 2,971,384 shares of the company’s stock worth $297,198,000 after acquiring an additional 818,309 shares during the period. Casdin Capital LLC bought a new position in shares of Guardant Health in the fourth quarter worth $79,016,000. D1 Capital Partners L.P. bought a new position in shares of Guardant Health in the fourth quarter worth $47,867,000. Finally, Iron Triangle Partners LP boosted its holdings in shares of Guardant Health by 131.7% in the fourth quarter. Iron Triangle Partners LP now owns 440,255 shares of the company’s stock worth $44,034,000 after acquiring an additional 250,255 shares during the period. 89.36% of the stock is owned by institutional investors.

Guardant Health Trading Up 2.2 %

NASDAQ GH opened at $59.28 on Monday. The stock’s 50-day simple moving average is $50.42 and its two-hundred day simple moving average is $51.68. Guardant Health, Inc. has a twelve month low of $27.65 and a twelve month high of $132.87. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of -10.96 and a beta of 0.80. The company has a quick ratio of 5.83, a current ratio of 6.18 and a debt-to-equity ratio of 3.56.

Guardant Health (NASDAQ:GHGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.00). Guardant Health had a negative net margin of 135.03% and a negative return on equity of 99.90%. The company had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. During the same period last year, the business posted ($0.96) earnings per share. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year. Research analysts forecast that Guardant Health, Inc. will post -6.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Piper Sandler assumed coverage on Guardant Health in a report on Thursday, June 2nd. They issued an “overweight” rating and a $65.00 price target for the company. OTR Global downgraded Guardant Health to a “positive” rating in a research report on Monday, August 1st. The Goldman Sachs Group lowered their price objective on Guardant Health from $90.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, August 8th. Credit Suisse Group initiated coverage on Guardant Health in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, Morgan Stanley lowered their price objective on Guardant Health from $85.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and an average target price of $115.75.

Insider Activity

In related news, insider Kumud Kalia sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $51.39, for a total value of $102,780.00. Following the sale, the insider now directly owns 18,530 shares of the company’s stock, valued at $952,256.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Kumud Kalia sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $51.39, for a total value of $102,780.00. Following the sale, the insider now directly owns 18,530 shares of the company’s stock, valued at $952,256.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Amelia Merrill sold 4,500 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $53.38, for a total value of $240,210.00. Following the completion of the sale, the senior vice president now directly owns 24,708 shares in the company, valued at $1,318,913.04. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

See Also

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.